These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20512334)

  • 1. Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
    Vici P; Fabi A; Metro G; Sergi D; Giannarelli D; Di Lauro L; Bepler G; Tomao F; Cognetti F; Conti F; Lopez M
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):687-93. PubMed ID: 20512334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
    Colomer R; Llombart-Cussac A; Lluch A; Barnadas A; Ojeda B; Carañana V; Fernández Y; García-Conde J; Alonso S; Montero S; Hornedo J; Guillem V
    Ann Oncol; 2004 Feb; 15(2):201-6. PubMed ID: 14760109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
    Morizane C; Okusaka T; Ueno H; Kondo S; Ikeda M; Furuse J; Shinichi O; Nakachi K; Mitsunaga S; Kojima Y; Suzuki E; Ueno M; Yamaguchi T
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
    Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
    Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
    Xu B; Jiang Z; Kim SB; Yu S; Feng J; Malzyner A; Del Giglio A; Chung HC; Shen LJ; Pen DL
    Breast Cancer; 2011 Jul; 18(3):203-12. PubMed ID: 21465229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
    J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment.
    Xu B; Shen Z; Jiang Z; Guan Z; Zhang X
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):320-9. PubMed ID: 21114782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
    Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
    Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
    Schmid P; Heilmann V; Schulz CO; Dieing A; Lehenbauer-Dehm S; Jehn C; Sezer O; Possinger K; Flath B
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):568-74. PubMed ID: 16044345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
    Airoldi M; Cattel L; Passera R; Pedani F; Delprino L; Micari C
    Am J Clin Oncol; 2006 Oct; 29(5):490-4. PubMed ID: 17023785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
    Morabito A; Filippelli G; Palmeri S; Cascinu S; Ferraù F; Zagonel V; Gattuso D; Catalano V; Capaccetti B; Franciosi V; Accurso V; Scinto F; Gasparini G
    Breast Cancer Res Treat; 2003 Mar; 78(1):29-36. PubMed ID: 12611454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Kouroussis Ch; Papakotoulas P; Kalbakis K; Tryfonidis K; Vardakis N; Poppis E; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 May; 69(5):1345-52. PubMed ID: 22349809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer.
    Stathopoulos GP; Rigatos SK; Pergantas N; Tsavdarides D; Athanasiadis I; Malamos NA; Stathopoulos JG
    J Clin Oncol; 2002 Jan; 20(1):37-41. PubMed ID: 11773151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.
    Tas F; Guney N; Derin D; Camlica H; Aydiner A; Topuz E
    Invest New Drugs; 2008 Aug; 26(4):363-8. PubMed ID: 18165864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
    Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.
    Tomao S; Romiti A; Tomao F; Di Seri M; Caprio G; Spinelli GP; Terzoli E; Frati L
    BMC Cancer; 2006 May; 6():137. PubMed ID: 16723016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.
    Zielinski CC
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):36-40. PubMed ID: 14768404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
    Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Botti G; Cortino GR; Di Bonito M; Rubulotta R; Vallone P; Comella G
    Oncology; 2002; 62(1):25-32. PubMed ID: 11810040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.